Sanofi (CHIX:SANP) 5-Year EBITDA Growth Rate : 6.00% (As of Jun. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Sanofi 5-Year EBITDA Growth Rate?

Sanofi's EBITDA per Share for the six months ended in Jun. 2024 was €3.65.

During the past 12 months, Sanofi's average EBITDA Per Share Growth Rate was -28.10% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -10.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 6.00% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 4.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Sanofi was 35.50% per year. The lowest was -10.90% per year. And the median was 3.20% per year.

Competitive Comparison of Sanofi's 5-Year EBITDA Growth Rate

For the Drug Manufacturers - General subindustry, Sanofi's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's 5-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Sanofi's 5-Year EBITDA Growth Rate falls into.

Sanofi 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Sanofi (CHIX:SANp) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Sanofi 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Sanofi's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (CHIX:SANp) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:USA SNY:Mexico 1SAN:Italy 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SNW:Bulgaria SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.